Please use this identifier to cite or link to this item:
Title: SARS-CoV-2 mRNA vaccination and Graves' disease: a report of 12 cases and review of the literature
Authors: Chee, Ying Jie
Liew, Huiling
Hoi, Wai Han
Lee, Yingshan
Lim, Brenda
Chin, Han Xin
Lai, Ray Tian Rui
Koh, Yunqing
Tham, Michelle
Seow, Cherng Jye
Quek, Zhi Han
Chen, Abel Weiliang
Quek, Timothy Peng Lim
Tan, Alvin Wai Kit
Dalan, Rinkoo
Keywords: Science::Medicine
Issue Date: 2022
Source: Chee, Y. J., Liew, H., Hoi, W. H., Lee, Y., Lim, B., Chin, H. X., Lai, R. T. R., Koh, Y., Tham, M., Seow, C. J., Quek, Z. H., Chen, A. W., Quek, T. P. L., Tan, A. W. K. & Dalan, R. (2022). SARS-CoV-2 mRNA vaccination and Graves' disease: a report of 12 cases and review of the literature. The Journal of Clinical Endocrinology & Metabolism, 107(6), e2324-e2330.
Project: MOH-000014
Journal: The Journal of Clinical Endocrinology & Metabolism
Abstract: Context and objective: Thyroid autoimmunity has been reported to be associated with severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) and the SARS-CoV-2 vaccination recently. We report a series of patients who presented with new onset or relapse of Graves’ disease-related hyperthyroidism shortly after receiving the SARS-CoV-2 messenger RNA (mRNA) vaccine at a single tertiary institution in Singapore. Methods and results: We describe 12 patients who developed hyperthyroidism within a relatively short interval (median onset, 17 [range, 5-63] days) after receiving the SARS-CoV-2 mRNA vaccine. The majority were females (11/12) with median age of 35.5 (range, 22-74) years. Six patients had new-onset hyperthyroidism, whereas the other 6 had relapse of previously well-controlled Graves’ disease. TSH receptor antibody concentrations ranged from 2.4 to 32 IU/L. The majority of the patients were able to go for the second dose of the vaccine without any further exacerbations. Literature review revealed 21 other similar cases reported from across the world. Conclusion: Our case series provides insight into the characteristics of individuals in whom Graves’ disease was triggered by the SARS-CoV-2 vaccination. Clinicians need to be vigilant of precipitation or exacerbation of autoimmune thyroid disorders in predisposed individuals after exposure to the SARS-CoV-2 vaccination. Further epidemiological and mechanistic studies are required to elucidate the possible associations between the SARS-CoV-2 vaccines and the development of thyroid autoimmunity.
ISSN: 0021-972X
DOI: 10.1210/clinem/dgac119
Rights: © The Author(s) 2022. Published by Oxford University Press on behalf of the Endocrine Society. All rights reserved.
Fulltext Permission: none
Fulltext Availability: No Fulltext
Appears in Collections:LKCMedicine Journal Articles

Citations 20

Updated on Jan 27, 2023

Web of ScienceTM
Citations 20

Updated on Jan 28, 2023

Page view(s)

Updated on Jan 28, 2023

Google ScholarTM




Items in DR-NTU are protected by copyright, with all rights reserved, unless otherwise indicated.